Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
The Staphylococcus aureus Map protein is an immunomodulator that interferes with T cell–mediated responses
Lawrence Y. Lee, … , Damien McDevitt, Eric L. Brown
Lawrence Y. Lee, … , Damien McDevitt, Eric L. Brown
Published November 15, 2002
Citation Information: J Clin Invest. 2002;110(10):1461-1471. https://doi.org/10.1172/JCI16318.
View: Text | PDF
Article Infectious disease

The Staphylococcus aureus Map protein is an immunomodulator that interferes with T cell–mediated responses

  • Text
  • PDF
Abstract

Research Article

Authors

Lawrence Y. Lee, Yuko J. Miyamoto, Bradley W. McIntyre, Magnus Höök, Kirk W. McCrea, Damien McDevitt, Eric L. Brown

×

Figure 7

Options: View larger image (or click on image) Download as PowerPoint
DTH following adoptive T cell transfer. DbpA-immunized mice were treated...
DTH following adoptive T cell transfer. DbpA-immunized mice were treated with either Map19 or Ace40, as described above. On day 7, mice were sacrificed and spleens were harvested and enriched for T cells by nylon wool purification. Cells (5 × 107) were injected intraperitoneally into syngeneic recipients. Twenty-four hours later, recipient mice were challenged with DbpA, and the DTH response was assessed as described above. T cells from DbpA-immunized Ace40-treated or T cells from DbpA-immunized (untreated) mice elicited a significant DTH response compared with unimmunized but challenged mice or to naive T cell–recipient mice (*P < 0.04; Student t test). T cells from DbpA-immunized, Map19-treated mice did not elicit a significant DTH response compared with positive control treatment groups (**P < 0.001; Student t test). Data are expressed as the mean ± SE of five mice.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts